Logo
x

Search

Subscribe Now

multiple

PharmaShots Interview: X4 Pharmaceuticals’ Paula Ragan Shares Insights on Mavorixafor for the Treatment of Multiple Immunodeficiencies

PharmaShots Interview: X4 Pharmaceuticals’ Paula Ragan Shares Insights on Mavorixafor for the Treatment of Multiple Immunodeficien...

  • May 3, 2022
Boehringer Ingelheim's Cyltezo (biosimilar- adalimumab) Receives the US FDA's sBLA Approval as the 1st Interchangeable Biosimilar for Multiple Chronic Inflammatory Diseases

Boehringer Ingelheim's Cyltezo (biosimilar- adalimumab) Receives the US FDA's sBLA Approval as the 1st Interchangeable Biosimilar...

  • October 18, 2021
Pfizer Signs a WW License Agreement with Pyxis to Develop and Commercialize Two ADC Candidates

Pfizer Signs a WW License Agreement with Pyxis to Develop and Commercialize Two ADC Candidates

  • March 19, 2021
BMS Collaborates with Molecular Templates to Develop Engineered Toxin Body Therapies for Cancer

BMS Collaborates with Molecular Templates to Develop Engineered Toxin Body Therapies for Cancer

  • February 12, 2021
Schrödinger Signs a $2.7B Agreement with BMS to Develop and Commercialize Therapies in Multiple Disease Areas

Schrödinger Signs a $2.7B Agreement with BMS to Develop and Commercialize Therapies in Multiple Disease Areas

  • November 24, 2020
Merck's Brenzys (etanercept- biosimilar) Receives Health Canada Approval for Multiple Indications

Merck's Brenzys (etanercept- biosimilar) Receives Health Canada Approval for Multiple Indications

  • September 16, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.